SMAD4 and pancreatic neoplasm: A previous study using a genetically defined pancreatic cancer cell panel, which tested the cancer cells’ responses to chemotherapeutic drugs, found that SMAD4-inactivated cancer cell lines were more sensitive to cisplatin and irinotecan by two- to fourfold, but they were only modestly less sensitive to gemcitabine [58].